S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
NASDAQ:GRPH

Graphite Bio (GRPH) Competitors

$2.38
+0.01 (+0.42%)
(As of 09/22/2023 ET)
Compare
Today's Range
$2.34
▼
$2.39
50-Day Range
$2.18
▼
$2.77
52-Week Range
$1.59
▼
$3.69
Volume
401,699 shs
Average Volume
96,171 shs
Market Capitalization
$137.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.33
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

GRPH vs. TCRX, ERYP, ORTX, SGMO, IPSC, OMGA, GRTS, INMB, MOLN, and TALS

Should you be buying Graphite Bio stock or one of its competitors? The main competitors of Graphite Bio include TScan Therapeutics (TCRX), ERYTECH Pharma (ERYP), Orchard Therapeutics (ORTX), Sangamo Therapeutics (SGMO), Century Therapeutics (IPSC), Omega Therapeutics (OMGA), Gritstone bio (GRTS), INmune Bio (INMB), Molecular Partners (MOLN), and Talaris Therapeutics (TALS). These companies are all part of the "biological products, except diagnostic" industry.

Graphite Bio vs.

Graphite Bio (NASDAQ:GRPH) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking.

Graphite Bio has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500.

TScan Therapeutics has higher revenue and earnings than Graphite Bio. Graphite Bio is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Graphite BioN/AN/A-$101.05M-$2.29-1.04
TScan Therapeutics$13.53M9.37-$66.22M-$2.89-0.92

Graphite Bio has a net margin of 0.00% compared to TScan Therapeutics' net margin of -497.11%. Graphite Bio's return on equity of -31.89% beat TScan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Graphite BioN/A -31.89% -28.31%
TScan Therapeutics -497.11%-67.32%-38.16%

Graphite Bio presently has a consensus target price of $3.33, suggesting a potential upside of 40.06%. TScan Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 333.96%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than Graphite Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Graphite Bio
1 Sell rating(s)
8 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.89
TScan Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Graphite Bio received 1 more outperform votes than TScan Therapeutics when rated by MarketBeat users. However, 57.89% of users gave TScan Therapeutics an outperform vote while only 37.50% of users gave Graphite Bio an outperform vote.

CompanyUnderperformOutperform
Graphite BioOutperform Votes
12
37.50%
Underperform Votes
20
62.50%
TScan TherapeuticsOutperform Votes
11
57.89%
Underperform Votes
8
42.11%

In the previous week, Graphite Bio had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 1 mentions for Graphite Bio and 0 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 0.00 beat Graphite Bio's score of -1.00 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Graphite Bio Negative
TScan Therapeutics Neutral

54.3% of Graphite Bio shares are owned by institutional investors. Comparatively, 67.7% of TScan Therapeutics shares are owned by institutional investors. 38.4% of Graphite Bio shares are owned by insiders. Comparatively, 8.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

TScan Therapeutics beats Graphite Bio on 10 of the 17 factors compared between the two stocks.


Get Graphite Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRPH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRPH vs. The Competition

Export to Excel
MetricGraphite BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$137.99M$2.69B$4.62B$6.27B
Dividend YieldN/A2.23%2.58%6.52%
P/E Ratio-1.047.72143.2913.69
Price / SalesN/A171.262,859.9471.53
Price / CashN/A24.5493.03100.49
Price / Book0.473.533.764.83
Net Income-$101.05M$62.26M$121.75M$186.05M
7 Day Performance3.48%0.11%-2.61%-3.10%
1 Month Performance0.85%-4.47%-2.06%-4.14%
1 Year Performance-22.48%21.68%9.60%5.52%

Graphite Bio Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCRX
TScan Therapeutics
2.1975 of 5 stars		$2.94
+1.7%		$11.50
+291.2%		-8.0%$140.59M$13.53M-1.02135Gap Down
ERYP
ERYTECH Pharma
0 of 5 stars		$4.03
-12.4%		N/A+722.7%$137.50M$32.66M0.0049News Coverage
ORTX
Orchard Therapeutics
2.0374 of 5 stars		$6.77
+12.8%		$24.50
+261.7%		+43.7%$136.34M$21.31M-1.51166High Trading Volume
SGMO
Sangamo Therapeutics
1.9678 of 5 stars		$0.85
-2.3%		$5.80
+585.9%		-84.4%$149.76M$111.30M-0.70478Analyst Upgrade
IPSC
Century Therapeutics
2.2307 of 5 stars		$2.23
-0.4%		$15.33
+587.6%		-77.2%$133.27M$5.20M-1.03163Positive News
OMGA
Omega Therapeutics
1.5988 of 5 stars		$2.75
-13.0%		$11.00
+300.0%		-51.5%$151.64M$2.07M-1.24116
GRTS
Gritstone bio
1.651 of 5 stars		$1.38
-2.1%		$7.00
+407.2%		-52.7%$131.24M$2.70M-1.10233News Coverage
INMB
INmune Bio
1.5062 of 5 stars		$7.26
-6.8%		$16.00
+120.4%		-0.4%$130.83M$370,000.00-4.9410Positive News
MOLN
Molecular Partners
0 of 5 stars		$4.32
-3.8%		N/A-23.2%$156.99M$198.70M-2.14168High Trading Volume
TALS
Talaris Therapeutics
1.9688 of 5 stars		$2.92
flat		$7.50
+156.8%		+20.6%$124.86MN/A-1.6384

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:GRPH) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -